Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole <i>versus</i> palbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast cancer.

Ther Adv Med Oncol · 2023 · PMC10722948 · PMID 38107828

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although ribociclib + letrozole was also associated with a numerically greater PFS than palbociclib + letrozole, this difference did not reach statistical significance.

also in 111,027 other papers

may be significantno p-value reported

The addition of variances may, to some extent, widen the CIs, thus making some relationships that may be significant otherwise become nonsignificant.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.